AuthorisedPhase II and Phase III (Integrated)Interventional

Effect of intravenous immunoglobulins on painful sensory neuropathy evaluated by aggregated N-of-one trials

At a glance

Status

Authorised

Phase

Phase II and Phase III (Integrated)

Sponsor

Sorlandet Sykehus HF

Enrolment target

Start

09 Dec 2022

Idiopathic painful small fiber neuropathy or sensory neuronopathy.

What is this study about?

Pain intensity the second week (mean of days 8, 10 and 13) after start of IVIG/placebo infusions scored on a numeric rating scale (NRS) ranging from 0 to 10

Who may be eligible?

Age 18 Years to any · Sex: All

Locations (1)

—
Norway

How to find out more

Official trial record

Always speak to your GP or specialist before deciding to take part in a study.